Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGIC phase 2 trial of DNTH103 in adults with generalized myasthenia gravis
MOH_2024-09-30_013596Phase 2Not yet recruiting
- Sponsor
- Dianthus Therapeutics, Inc
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of claseprubart in myasthenia gravis (MG) (3 arms), sponsored by Dianthus Therapeutics, Inc. Primary endpoint: Safety and tolerability of DNTH103. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
claseprubart
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on MOH_2024-09-30_013596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-30_013596.